Patent "Selective Nox-1 inhibitor peptides and uses thereof" whose licence has been attributed to ProGeLife by SATT Aquitaine Transfert has been delivered in USA under N° US105179 ...
Patent " Proteasome inhibitors for treating a disorder related to an accumulation of non-degraded abnormal protein or a cancer" co-owned by ProGeLife has been granted by European P ...
[FranceBleu] "Children of the Moon" discovered a night dive in Annecy lake
Night dive in Marseille's bay by Children of the Moon
[AGENCY PRESS] : ANNECY : ProGeLife diving with the "Children of the Moon"
ProGeLife participated to the International Symposium on XP and other nucleotide excision repair disorders
ProGeLife participes to the General meeting of the french association "Children of the Moon" in Bellegarde sur Valsérine
Frédéric Bénéton became ProGeLife CEO
Patent "Selective Nox-1 inhibitor peptides and uses thereof" whose licence has been attributed to ProGeLife by SATT Aquitaine Transfert has been delivered in Tunisia under N° 2455 ...
ProGeLife participates to Recherch'Thon for the second year
PGL101 peptide received "Orphan Drug Designation" (ODD) from the FDA (US Food and Drug Administration) for the treatment of Xeroderma pigmentosum
The team led by Professor Nicolas Lévy published the discovery of a new molecule for the treatment of progeria in EMBO Molecular Medicine scientific journal
ProGeLife gets 730,000 euros from Bpifrance (innovation aid - ADI) for the development of PGL101 peptide in the prevention and treatment of skin cancers.
ProGeLife participates to the Health Future Show organized by Interpro Santé Provence (UP13) and Eurobiomed
ProGeLife participates to the European Xeroderma pigmentosum Society (EXPS) meeting
Eric Dessaud joins ProGeLife as Head of Clinical Development
ProGeLife raises 1.3M€ from private investors
ProGeLife hires a skilled engineer, Pascale Klopp, to strengthen his R&D team
ProGeLife strengthens his team with Gaëlle Odelin, Doctor in Veterinary Medicine (DVM) , PhD, as research project leader
ProGeLife obtained a financial help from Impulse Incubator
ProGeLife is selected to the First international biotechnology meeting (Rencontres Internationales de Biotechnologies, RIB 2015)
ProGeLife completes his team by hiring Héloïse Laroye as Clinical Research Coordinator
ProGeLife working on UV-induced skin aging and cancer
ProGeLife signs an exclusive licensing agreement with Aquitaine Science Transfert for the development of InhNOX technology in health domain.
ProGeLife generates his R&D team through the hiring of two PhD biologists, Sophie Perrin and Claire Navarro, as research project leader.
PGL101 (InhNOX1) peptide get from EMA the designation of "Orphan Drug Designation" (ODD) for the prevention and the treatment of Xeroderma pigmentosum disease.
ProGeLife is founded by Nicolas Lévy (MD, PhD, Professor in Medical Genetics, Hospital Practitioner), Pierre Cau (MD, PhD, Professor in Cell Biology, Hospital Practitioner) and se ...
An excellent R&D team focuses its research on two extremely rare genetic diseases of children characterized by accelerated or premature aging: ProgeriaProgeria : This paradigmatic disease of aging is also known as Hutchinson-Gilford syndrome. Extremely rare genetic disease (aroung 300 living patients worldwide) characterized by an accelerated and premature aging due to the abnormal accumulation of progerin. and Xeroderma pigmentosumXeroderma pigmentosum : A group of rare genetic diseases characterized by a defect in one of the DNA repair pathways. Depending on the mutated protein, eight XP diseases are known, XPA to XPG and XPV. (the "Children of the Moon" disease).
ProGeLife is patenting and developing innovative and adapted treatments:
- in the first instance to the paediatric population
- further applied to age-related diseases that are more common in the general population.